Promedior R&D is comprised of a novel drug discovery platform to regulate
the monocyte-derived cell populations that play key roles in fibrotic,
inflammatory and autoimmune diseases. By specifically targeting these
cells at the site of injury, Promedior is able to treat the source of aberrant
immune system responses, promote tissue healing and resolution and greatly
reduce the risk of systemic side effects inherent in current therapeutic
approaches.
Recent discoveries regarding the biology of fibrotic, inflammatory and
autoimmune diseases suggest that there are common cellular mechanisms that
control the initiation and progression of many of these diseases. One key
cell type, called the monocyte, can either promote resolution of disease and
healing or conversely progression of disease. A large number of diverse
and redundant stimuli can drive the monocyte down the wrong path toward tissue
destruction and/or fibrosis. Existing therapeutic approaches to many
of these diseases are ineffective, because they either target only a single
redundant stimuli or are so broad in activity that they prevent monocyte-driven
resolution.
